New Delhi, 10 October 2025: ENTOD Pharmaceuticals, a global leader in eye health innovation, has announced the launch of OCUBIOME™, India’s first ocular probiotic blend developed to support healthy eyes. The proprietary formulation was created at the company’s advanced R&D centre in Navi Mumbai.
Addressing Modern Eye Health Challenges
In today’s fast-paced, screen-heavy lifestyle, issues like dry eye syndrome, ocular discomfort, and post-surgical recovery complications are increasingly common. Millions experience symptoms such as burning eyes, blurred vision, and eye fatigue. While lubricants provide temporary relief, long-term management remains a challenge.
OCUBIOME™ offers a holistic approach by restoring the balance of both ocular and gut microbiota, complementing traditional therapies and providing sustained benefits beyond immediate relief.
A Convenient Daily Routine
Delivered in mouth-melting, no-added-sugar sachets, OCUBIOME™ is designed for once-daily use. It supports ocular comfort, digital eye strain recovery, and promotes long-term eye health in a simple and convenient way.
Expert Insights
“Eye health today cannot be addressed in isolation – it is impacted by lifestyle, environment, and recovery needs after surgery. With OCUBIOME™, ENTOD is introducing a category-first innovation that brings freshness and convenience to how we manage ocular wellness,”
— Mr. Nikkhil K Masurkar, CEO, ENTOD Pharmaceuticals.
“Ocular health must be considered within the broader systemic context. Evidence shows that the gut microbiome plays a direct role in ocular inflammation and disease progression. ENTOD’s probiotic innovation provides clinicians with a scientifically supported option to improve outcomes in conditions such as dry eye and post-surgical recovery,”
— Dr. Hitesh Chheda, Medical Director, Asian Eye Institute & Laser Centre.
A New Era in Preventive Eye Care
The launch of OCUBIOME™ represents a turning point in proactive ocular wellness, aligning with growing scientific interest in the gut–eye axis. By bridging gut and eye health, ENTOD aims to empower patients and clinicians with a preventive, science-backed solution that goes beyond symptom relief.
Availability: OCUBIOME™ will be available by prescription from November 2025.
About ENTOD Pharmaceuticals
ENTOD Pharmaceuticals is a global research-driven pharmaceutical company with over 48 years of expertise in Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2000+ strong global team, and presence in 67 countries, ENTOD adheres to the highest GMP and European-certified quality standards, continuing to pioneer innovation in eye health.
